Related Experiment Video
Updated: May 24, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Curative one-shot systemic virotherapy in murine myeloma
S Naik1, R Nace, M J Federspiel
1Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Leukemia
|March 20, 2012
Summary
A novel oncolytic virus effectively treats multiple myeloma by destroying tumors and stimulating an immune response. This single-dose therapy offers a potential cure for multiple myeloma by targeting both bulky and residual disease.
Area of Science:
- Oncolytic virotherapy
- Immunotherapy
- Multiple Myeloma Research
Background:
- Current multiple myeloma therapies are complex and lengthy.
- Oncolytic viruses show potential for tumor debulking and residual disease elimination, but this remains unproven.
Purpose of the Study:
- To engineer an oncolytic vesicular stomatitis virus for multiple myeloma treatment.
- To minimize neurotoxicity, enhance antimyeloma immunity, and enable noninvasive monitoring.
- To establish a curative oncolytic paradigm for multiple myeloma.
Main Methods:
- Engineered an oncolytic vesicular stomatitis virus.
- Administered virus intravenously to immunocompetent myeloma-bearing mice.
- Utilized high-resolution imaging, autoradiography, and immunohistochemistry for analysis.
Main Results:
- Virus extravasated tumor blood vessels, forming infectious centers that caused extensive tumor destruction.
- Tumor debulking occurred within 72 hours, before significant antiviral antibody response.
- Antimyeloma T cells eliminated residual uninfected myeloma cells.
Conclusions:
- A single intravenous dose of the engineered virus can mediate both direct tumor debulking and immune eradication of minimal residual disease.
- This establishes a potentially curative oncolytic paradigm for multiple myeloma.
- Clinical translation of this therapy is currently in progress.
